Collegium Pharmaceutical (NASDAQ:COLL) Given a $33.00 Price Target by Needham & Company LLC Analysts

Needham & Company LLC set a $33.00 price objective on Collegium Pharmaceutical (NASDAQ:COLL) in a research report report published on Friday morning, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

COLL has been the subject of several other reports. Cantor Fitzgerald restated an overweight rating and issued a $24.00 target price (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. BidaskClub upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, August 13th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, October 11th. ValuEngine upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, August 1st. Finally, William Blair restated a buy rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $24.00.

Shares of COLL stock opened at $11.56 on Friday. The company has a market capitalization of $404.32 million, a PE ratio of -9.71 and a beta of 0.52. The firm has a fifty day simple moving average of $11.54 and a 200-day simple moving average of $12.33. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. Collegium Pharmaceutical has a twelve month low of $10.01 and a twelve month high of $19.83.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $75.04 million during the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) earnings per share. Equities research analysts predict that Collegium Pharmaceutical will post -0.51 EPS for the current year.

In related news, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total value of $257,534.90. Following the sale, the director now directly owns 64,223 shares of the company’s stock, valued at $748,197.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.08% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in Collegium Pharmaceutical by 19.1% in the second quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after acquiring an additional 693,812 shares in the last quarter. BlackRock Inc. raised its holdings in Collegium Pharmaceutical by 7.1% in the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after acquiring an additional 165,018 shares in the last quarter. Vanguard Group Inc. raised its holdings in Collegium Pharmaceutical by 1.5% in the second quarter. Vanguard Group Inc. now owns 1,571,474 shares of the specialty pharmaceutical company’s stock valued at $20,665,000 after acquiring an additional 22,883 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in Collegium Pharmaceutical by 5.8% in the second quarter. Rice Hall James & Associates LLC now owns 1,260,690 shares of the specialty pharmaceutical company’s stock valued at $16,578,000 after acquiring an additional 69,549 shares in the last quarter. Finally, Cortina Asset Management LLC raised its holdings in Collegium Pharmaceutical by 81.0% in the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after acquiring an additional 228,035 shares in the last quarter. 92.08% of the stock is currently owned by hedge funds and other institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Story: What are the benefits of buying treasury bonds?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.